Evidence map›Paper›PMID 40226484›Full record

ArticlePreventive medicine reports2025

Acceptability of

Susana L Matias, Caitlin D French, Jessica Saavedra, Akshara Shankar, Aidan S Rymland, Ivan Rodriguez Beltran, Jose O Collado, Carrie Waterman

Abstract read
In one paragraph

Article in Preventive medicine reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Harnessing the anticancer potential ofAnnals of medicine and surgery (2012) · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Susana L MatiasDepartment of Nutritional Sciences & Toxicology, University of California, Berkeley, CA, USA.
Caitlin D FrenchDepartment of Nutritional Sciences & Toxicology, University of California, Berkeley, CA, USA.
Jessica SaavedraDepartment of Nutritional Sciences & Toxicology, University of California, Berkeley, CA, USA.
Akshara ShankarDepartment of Nutritional Sciences & Toxicology, University of California, Berkeley, CA, USA.
Aidan S RymlandDepartment of Nutritional Sciences & Toxicology, University of California, Berkeley, CA, USA.
Ivan Rodriguez BeltranDepartment of Nutritional Sciences & Toxicology, University of California, Berkeley, CA, USA.
Jose O ColladoDepartment of Nutritional Sciences & Toxicology, University of California, Berkeley, CA, USA.
Carrie WatermanDepartment of Nutrition, University of California, Davis, CA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: To assess the acceptability of moringa leaf powder, a nutrient-dense plant that has been mostly tested in pre-clinical studies. Methods: We conducted an acceptability study of different doses of moringa leaf powder in California in 2023. Participants were randomly assigned to one of the three groups (one tsp. ≈ 2.4 g [low dose], two tsp. ≈ 4.8 g [medium dose], or three tsp. ≈ 7.2 g [high dose]) and instructed to consume the moringa powder with foods or beverages for seven days. Participants were interviewed and had their skin carotenoid levels measured at baseline and endline and completed daily surveys on consumption and side effects. The study outcomes were consumption (number of days it was consumed), liking (sum of organoleptic characteristics ratings) and side effects (number of symptoms reported). Results: Fifty-two participants were enrolled; 96 % completed the study. The number of days that moringa was consumed (Median = 7, Interquartile range:7,7), changes in skin carotenoid levels, and total liking scores did not differ by dose group ( Conclusions: Compliance in consuming moringa was high for all groups, suggesting that all three doses tested may be acceptable in future moringa supplementation trials. GI symptoms may occur more frequently when the moringa doses are higher than 7 g/day, but they tend to be mild and transient.

Indexed as

AcceptabilityConsumptionHealthy adultsMoringaMoringa oleiferaSide effects

Identifiers

PMID40226484
PMCPMC11986971

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.